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TG    ……………………………………………………………………. …………. Triglyceride 
LDL   ……………………………………………………………..  Low Density lipoprotein 
HDL...………………………………………………………....    High Density lipoprotein 
CRP  ………………………………………………………………..   Cross reacting Protein 
Cr     …………………………………………………………………………………… Creatinine 
Lp(a)  …………………………………………….…………………………….   Lipoprotein(a) 
VLDL  ………………………………….………………… Very Low Density Lipoprotein 
SREBPs ………………………….….  Sterol Regulatory Element-Binding protein 
 - ALA  …………………………………………………………………...   - Linolenic Acid 
EPA    …………….………………………………………………….  Eicosapentanoic Acid 
DHA   ……………………………………………………………….. Docosa Hexanoic Acid 
GFR    ………………………………………………………..   Glomerular Filtration Rate 
BW   ……………………………………………………………………………….  Body Weight 
CKD   ……………………………………………………………..   Chronic Kidney Disease 
ESRD   …………………………………………………………..  End Stage Renal Disease 
CRRT   ………………………………….  Continues Renal Replacement Therapies 
SLED    …………………………………………………….  Slow Low-efficiency Dialysis 
ASCVD ……………………………………   Atherosclerotic Cardiovascular Disease 
GPIHBP1   ………………….. Glycosylphospha!dylinositol -anchored Protein 
ABCA1     …………………………………………….ATP-Binding Casse"e Protein A1 
LCAT   ………………………………………….  Licetine cholesterol Acetyl transfers 
CETP   ………………………………………………. Cholestrol Ester Transfer Protein 
SR-BI   ………………………………………………………  Scavenger receptor Class B1 
PLTP     ………………………………………………….. Phospholipid Transfer Protein  
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